Rani Therapeutics Holdings, Inc.

NASDAQ:RANI

Biotechnology

Healthcare
$0.80 -5.22%

-$0.04 today

Market cap
$52.19M
Beta
0.76
P/E (TTM)
-4.6
EPS (TTM)
-$0.16
52W Low $0.39High $3.87

Volume 0.23M

Average 1.15M

RANI Retained Earnings

Cumulative profits kept in the business rather than paid out as dividends.

Rani Therapeutics Holdings, Inc.NASDAQ: RANI

Retained Earnings · Q1 FY2026 · quarter ended Mar 2026

Retained earnings remains negative

Q1 FY2026 retained earnings was -$139.61M, compared with -$110.17M a year earlier.

Context

  • Retained earnings amounted to 269.1% of total assets at the end of Q1 FY2026, down 187.6 pp from a year earlier.
  • Retained earnings grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether retained earnings keeps falling in the next quarterly balance sheet after a -26.7% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$139.61M-5.3% QoQ
Last fiscal yearDec 2025
-$132.58M-28.8% YoY
Year agoMar 2025
-$110.17M-26.7% since
Retained Earnings past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-26.7%——
1 year-28.8%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Retained Earnings history

USD · from the balance sheet

Latest · FY2025
(132.58M) USD
Year-over-year change
-28.8%

Retained Earnings vs competitors

How RANI compares with its peers on the latest reported figures

  • Peers report in different currencies, so retained earnings is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -26.7% is the lowest of 9, against a peer median of -17.4%.
  • Retained earnings amounts to 269.1% of total assets for RANI, versus a peer median of 547.4%.
RANI Competitors
Retained Earnings for RANI and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
RANIRani Therapeutics Holdings, Inc.Mar 2026-$139.61M USD-26.7%—269.1%
ELTXElicio Therapeutics, Inc.Mar 2026-$245.5M USD-19.6%—1082.0%
MOLNMolecular Partners AGMar 2026-CHF 323.66M CHF-24.1%—370.3%
IPHAInnate Pharma S.A.Dec 2025-€435.36M EUR-12.7%—694.4%
CRDFCardiff Oncology, Inc.Mar 2026-$442.38M USD-11.3%—899.6%
MISTMilestone Pharmaceuticals Inc.Mar 2026-$456.67M USD-17.6%—235.7%
CRBPCorbus Pharmaceuticals Holdings, Inc.Mar 2026-$578.4M USD-17.1%—400.3%
TNXPTonix Pharmaceuticals Holding Corp.Mar 2026-$894.91M USD-19.7%—347.0%
SGMOSangamo Therapeutics, Inc.Mar 2026-$1.66B USD-8.0%—2765.4%
Peer median (excluding RANI) —-17.4%—547.4%

Competitors are the stored peer set for RANI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents117.45M27.01M5.86M3.76M18.62M
Short-term Investments071.48M42.68M23.88M31.09M
Net Receivables00200K428K2.04M
Inventory00000
Other Current Assets0500K800K1.68M1.57M
Total Current Assets119.6M100.92M50.85M29.74M53.32M
Property, Plant & Equipment (Net)4.61M7.1M6.82M6.64M5.05M
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets00246K246K246K
Total Non-current Assets4.61M7.1M7.07M6.89M5.3M
Total Assets124.21M108.03M57.92M36.63M58.62M
Account Payables1.08M1.46M648K1.36M309K
Short-term Debt004.9M15M0
Tax Payables00000
Deferred Revenue001.21M06.83M
Other Current Liabilities398K591K202K283K46K
Total Current Liabilities2.64M4.82M7.99M19.89M12.67M
Long-term Debt029.15M24.48M9.61M2.73M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00001.71M
Other Non-current Liabilities00000
Total Non-current Liabilities029.21M24.48M13.25M4.44M
Total Liabilities2.64M34.02M32.47M33.14M17.11M
Common Stock5K5K5K5K11K
Retained Earnings(8.33M)(38.92M)(72.89M)(102.91M)(132.58M)
Accumulated OCI(0)(73K)(12K)5K1K
Other Stockholders Equity(2)0000
Minority Interest74.16M37.15M12.58M1.5M8.5M
Total Equity121.57M74M25.44M3.49M41.51M
Total Debt030.21M30.1M29.71M4.32M
Net Debt(117.45M)3.21M24.24M25.95M(14.3M)

Rani Therapeutics Holdings, Inc.

NASDAQ:RANI

Intrinsic Alpha fair value

Locked

Current Price

$0.80

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.